Flessa H C, Glueck H I
Arch Otolaryngol. 1977 Mar;103(3):148-51. doi: 10.1001/archotol.1977.00780200074007.
The combination of a progestogen and an estrogen (Enovid, Enovid E) has been used successfully in the management of nine patients with hereditary hemorrhagic telangiectasia (HHT) and severe epistaxis: Such therapy was instituted when epistaxis was severe and only after other therapeutic measures had failed. Seven of our patients required the 5-mg tablet (Enovid) to achieve a satisfactory clinical result; two patients received the 2.5-mg preparation (Enovid E). The eight women received cyclic therapy; the man received therapy without interruption. Because of the possibility of serious adverse effects from the drugs, it is required that each patient receive a complete medical evaluation prior to therapy and at frequent intervals while receiving therapy. Enovid therapy for HHT is not recommended for the patient with mild bleeding that can be controlled by conventional therapy.
一种孕激素和一种雌激素的组合（炔雌醇甲醚片、炔雌醇甲醚-炔诺酮片）已成功用于治疗9例遗传性出血性毛细血管扩张症（HHT）和严重鼻出血患者：仅在鼻出血严重且其他治疗措施均失败后才采用这种治疗方法。我们的7例患者需要服用5毫克片剂（炔雌醇甲醚片）才能取得满意的临床效果；2例患者服用的是2.5毫克制剂（炔雌醇甲醚-炔诺酮片）。8名女性接受周期性治疗；男性接受不间断治疗。由于这些药物可能产生严重不良反应，因此要求每位患者在治疗前接受全面的医学评估，并在接受治疗期间定期进行评估。对于轻度出血可通过常规治疗控制的患者，不建议采用炔雌醇甲醚片治疗HHT。
